CSL Future Growth

Future criteria checks 3/6

CSL is forecast to grow earnings and revenue by 13.1% and 6.6% per annum respectively. EPS is expected to grow by 13.2% per annum. Return on equity is forecast to be 18.7% in 3 years.

Key information

13.1%

Earnings growth rate

13.2%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	6.6%
Future return on equity	18.7%
Analyst coverage	Good
Last updated	14 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BRSE:CSJ - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	18,064	4,129	4,052	4,953	13
6/30/2026	16,923	3,633	3,534	4,368	14
6/30/2025	15,777	3,095	2,922	3,813	14
6/30/2024	14,800	2,642	1,506	2,764	N/A
3/31/2024	14,490	2,557	1,332	2,727	N/A
12/31/2023	14,179	2,472	1,158	2,690	N/A
9/30/2023	13,745	2,333	1,034	2,646	N/A
6/30/2023	13,310	2,194	909	2,601	N/A
3/31/2023	12,507	2,156	765	2,392	N/A
12/31/2022	11,705	2,118	622	2,182	N/A
9/30/2022	11,133	2,186	1,001	2,406	N/A
6/30/2022	10,562	2,255	1,381	2,629	N/A
3/31/2022	10,587	2,290	1,251	2,679	N/A
12/31/2021	10,612	2,325	1,121	2,728	N/A
9/30/2021	10,461	2,350	1,538	3,175	N/A
6/30/2021	10,310	2,375	1,955	3,622	N/A
3/31/2021	10,145	2,520	2,127	3,597	N/A
12/31/2020	9,980	2,665	2,299	3,571	N/A
9/30/2020	9,565	2,384	1,710	3,030	N/A
6/30/2020	9,151	2,103	1,121	2,488	N/A
3/31/2020	9,048	2,054	1,009	2,418	N/A
12/31/2019	8,944	2,006	897	2,347	N/A
9/30/2019	8,742	1,962	628	1,996	N/A
6/30/2019	8,539	1,919	360	1,644	N/A
3/31/2019	8,406	1,861	426	1,621	N/A
12/31/2018	8,274	1,803	492	1,597	N/A
9/30/2018	8,094	1,766	701	1,750	N/A
6/30/2018	7,915	1,729	910	1,902	N/A
3/31/2018	7,666	1,674	N/A	1,662	N/A
12/31/2017	7,417	1,618	N/A	1,422	N/A
9/30/2017	7,182	1,478	N/A	1,335	N/A
6/30/2017	6,947	1,337	N/A	1,247	N/A
3/31/2017	6,802	1,333	N/A	1,192	N/A
12/31/2016	6,656	1,329	N/A	1,138	N/A
9/30/2016	6,386	1,286	N/A	1,158	N/A
6/30/2016	6,115	1,242	N/A	1,179	N/A
3/31/2016	5,983	1,324	N/A	1,296	N/A
12/31/2015	5,850	1,406	N/A	1,413	N/A
9/30/2015	5,654	1,392	N/A	1,388	N/A
6/30/2015	5,459	1,379	N/A	1,364	N/A
3/31/2015	5,482	1,366	N/A	1,434	N/A
12/31/2014	5,505	1,354	N/A	1,504	N/A
9/30/2014	5,420	1,330	N/A	1,432	N/A
6/30/2014	5,335	1,307	N/A	1,361	N/A
3/31/2014	5,189	1,270	N/A	1,257	N/A
12/31/2013	5,042	1,233	N/A	1,154	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSJ's forecast earnings growth (13.1% per year) is above the savings rate (0.3%).

Earnings vs Market: CSJ's earnings (13.1% per year) are forecast to grow faster than the Swiss market (11.6% per year).

High Growth Earnings: CSJ's earnings are forecast to grow, but not significantly.

Revenue vs Market: CSJ's revenue (6.6% per year) is forecast to grow faster than the Swiss market (4.3% per year).

High Growth Revenue: CSJ's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CSJ's Return on Equity is forecast to be low in 3 years time (18.7%).

CSL Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited Provides Financial Guidance for Fiscal 2022

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

New minor risk - Financial position

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

High number of new directors

CSL Limited Provides Financial Guidance for Fiscal 2022

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies